Canaccord Genuity Maintains Hold on Vertex Pharmaceuticals, Lowers Price Target to $437

Canaccord Genuity analyst Whitney Ijem maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and lowers the price target from $441 to $437.